Atlas Trials

Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Clinical trial NCT05164042 · UNKNOWN

Trial details

NCT number
NCT05164042
Sponsor
Shenzhen University General Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapse LeukemiaRefractory Leukemia
Start date
2021-02-05
Primary completion
2024-02-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.